Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae

Microbial Drug Resistance

Volumn 14, Issue 3, 2008, Pages 187-196

  Davies, Todd A ^a   Yee, Y Cheung ^b   Bush, Karen ^a   Sahm, Dan ^c   Evangelista, Alan ^b   Goldschmidt, Raul ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; PNEUMOCOCCAL PENTAVALENT CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; DNA SEQUENCE; DRUG EFFECT; GENE MUTATION; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CHI-SQUARE DISTRIBUTION; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MENINGOCOCCAL VACCINES; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; REGRESSION ANALYSIS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

STREPTOCOCCUS PNEUMONIAE;

EID: 51349168159     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2008.0805     Document Type: Article

References (32)

1. Bartlett, J.G., S.F. Dowell, L.A. Mandell, T.M. File, Jr., D.M. Musher, and M.J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.
2. Bogaert, D., R. de Groot, and P.W.M. Hermans. 2004. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect. Dis. 4:144 -154.
3. Bogaert, D., A. van Belkum, M. Sluijter, A. Luijendijk, R. de Groot, H.C. Rumke, H.A. Verbrugh, and P.W. Hermans. 2004. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 363:1871-1872.
4. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 46:1-24.
5. Centers for Disease Control and Prevention. 2000. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 49:1-36.
6. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Morb. Mortal. Wkly. Rep. 54:893-897.
7. Clinical Laboratories Standards Institute (CLSI). 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA. CLSI document M7-A7.
8. Clinical Laboratories Standards Institute (CLSI). 2007. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Wayne, PA. CLSI document M100-S17.
9. Davies, T.A., A. Evangelista, S. Pfleger, K. Bush, D.F. Sahm, and R. Goldschmidt. 2002. Prevalence of single mutations in topoisomerase type II genes among levofloxacinsusceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46:119-124.
10. Davies, T.A., R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D.F. Sahm, and A. Evangelista. 2003. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant United States clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52:168-175.
11. Draghi, D.C., A.E. Evangelista, Y.C. Yee, and D.F. Sahm. 2005. Comparative analysis of antimicrobial phenotypes between Streptococcus pneumoniae (SP) populations isolated from the community and hospital settings. In Programs and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, p. 95.
12. Hammitt, L.L., D.L. Bruden, J.C. Butler, H.C. Baggett, D.A. Hurlburt, A. Reasonover, and T.W. Hennessy. 2006. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193:1487-1494.
13. Hausdorff, W.P., J. Bryant, P.R. Paradiso, and G.R. Siber. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30:100-121.
14. Hausdorff, W.P., D.R. Feikin, and K.P. Klugman. 2005. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis. 5:83-93.
15. Johnson, C.N., D.E. Briles, W.H. Benjamin, Jr., S.K. Hollingshead, and K.B. Waites. 2005. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg. Infect. Dis. 11:814-820.
16. Korzheva, N., and R. Goldschmidt. 2003. Comparison of fitness between isogenic strains of Streptococcus pneumoniae carrying Ser71Phe and Ser71Tyr substitutions in the QRDR region of the DNA topoisomerase IV parC gene. In Program and abstracts of the 103rd General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, DC, p. 23.
17. Kyaw, M.H., R. Lynfield, W. Schaffner, A.S. Craig, J. Hadler, A. Reingold, A.R. Thomas, L.H. Harrison, N.M. Bennett, M.M. Farley, R.R. Facklam, J.H. Jorgensen, J. Besser, E.R. Zell, A. Schuchat, and C.G. Whitney; Active Bacterial Core Surveillance of the Emerging Infections Program Network. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463.
18. Lexau, C.A., R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M.M. Farley, L.H. Harrison, W. Schaffner, A. Reingold, N.M. Bennett, J. Hadler, P.R. Cieslak, C.G. Whitney, G. Rothrock, P. Daily, S. Brooks, E. Lucas, S. Phelps, D. Vugia, J. Nadle, M. Apostol, A. Grey, N.L. Barrett, S. Petit, Z. Fraser, P. Mshar, R. Howard, C.D. Payne, P. Martell-Cleary, A. McDonald, J.C. Howgate, S. Segler, M.C. Johns, W. Baughman, D.S. Stephens, L.T. Sanza, J. Benton, A.B. Schmidt, K.D. Holmes, J. Langford, L. Triden, B. Jewell, J. Rainbow, C. Morin, B. Anderson, S. Zansky, G. Smith, C. Long, L. Duke, K. Stefonek, M. Barber, A.S. Craig, B. Barnes, A. Ingram, D. Levine, D. Gerber, A. Faulk, E.J. Boothe, S. Hanna, M. McMillian, A. Schuchat, C. van Beneden, T. Hilger, C. Wright, K.A. Robinson, S. Mathis, D.M. Jackson, and A.R. Franklin. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J. Am. Med. Assoc. 294:2043-2051.
19. Lim, S., D. Bast, A. McGeer, J. de Azavedo, and D.E. Low. 2003. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9:833-837.
20. Lipsitch, M. 1999. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5:336-345.
21. McDougal, L.K., R. Facklam, M. Reeves, S. Hunter, J.M. Swenson, B.C. Hill, and F.C. Tenover. 1992. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob. Agents Chemother. 36:2176-2184.
22. Muñoz, R., T. Coffey, M. Daniels, C. Dowson, G. Laible, J. Casal, R. Hakenbeck, M. Jacobs, J. Musser, B. Spratt, and A. Tomasz. 1991. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J. Infect. Dis. 164:302-306.
23. Niederman, M.S., L.A. Mandell, A. Anzueto, J.B. Bass, W.A. Broughton, G.D. Campbell, N. Dean, T. File, M.J. Fine, P.A. Gross, F. Martinez, T.J. Marrie, J.F. Plouffe, J. Ramirez, G.A. Sarosi, A. Torres, R. Wilson, and V.L. Yu. 2001. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163:1730-1754.
24. Pai, R., M.R. Moore, T. Pilishvili, R.E. Gertz, C.G. Whitney, and B. Beall. 2005. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192:1988-1995.
25. Pan, X.-S., J. Ambler, S. Mehtar, and L.M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
26. Pelton, S.I., A.M. Loughlin, and C.D. Marchant. 2004. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr. Infect. Dis. J. 23:1015-1022.
27. Regev-Yochay, G., R. Dagan, M. Raz, Y. Carmeli, B. Shainberg, E. Derazne, G. Rahav, and E. Rubinstein. 2004. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. J. Am. Med. Assoc. 292:716-720.
28. Robbins, J.B., R. Austrian, C.-J. Lee, S.C. Rastogi, G. Schiffman, J. Henrichsen, P.H. Mäkelä, C.V. Broome, R.R. Facklam, R.H. Tiesjema, and J.C. Parke, Jr. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136-1159.
29. Robinson, K.A., W. Baughman, G. Rothrock, N.L. Barrett, M. Pass, C. Lexau, B. Damaske, K. Stefonek, B. Barnes, J. Patterson, E.R. Zell, A. Schuchat, and C.G. Whitney. 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. J. Am. Med. Assoc. 285:1729- 1735.
30. Rozen, D.E., L. McGee, B.R. Levin, and K.P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:412-416.
31. Stephens, D.S., S.M. Zughaier, C.G. Whitney, W.S. Baughman, L. Barker, K. Gay, D. Jackson, W.A. Orenstein, K. Arnold, and A. Schuchat. 2005. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365:855-863.
32. Veenhoven, R., D. Bogaert, C. Uiterwaal, C. Brouwer, H. Kiezebrink, J. Bruin, E. Ijzerman, P. Hermans, R. de Groot, B. Zegers, W. Kuis, G. Rijkers, A. Schilder, and E. Sanders. 2003. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet 361:2189-2195.